EMA Says Yes To PRIME Designations For Wet AMD & HAE Gene Therapies

Two gene therapies, from Molecular Therapeutics and Intellia Therapeutics respectively, are among the four new products the European Medicines Agency accepted onto it priority medicines scheme this month.

gene and color background
Two new gene therapy candidates have won PRIME designation • Source: Shutterstock

NTLA-2002 and 4D-150, which are single-dose, gene therapy candidates for hereditary angioedema and neovascular age-related macular degeneration (wet AMD) respectively, are among the latest products to be accepted onto PRIME, the European Medicines Agency’s priority medicines scheme for drugs for unmet medical needs.

Key Takeaways

  • Two gene therapies and two biological drugs were accepted onto the European Medicines Agency’s PRIME scheme in October, and three applications for PRIME designation were rejected.

NTLA-2002, from Intellia Therapeutics, and 4D-150, from Molecular Therapeutics, were among four investigational products that secured a PRIME...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography